Alpha Tau data adds to ‘robust list of evidence,’ says Cantor Fitzgerald

Cantor Fitzgerald reiterates an Overweight rating on Alpha Tau Medical with a $23 price target saying the company presented some longer-term data supporting the Alpha DaRT platform, “which adds to the already robust list of evidence in superficial tumors.” The company’s “unique” implantation method could avoid many potential toxicity problems for both patients and providers, the analyst tells investors in a research note.